MFG
ACHV icon

Magnus Financial Group’s Achieve Life Sciences ACHV Stock Holding History

Magnus Financial Group’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,750
Closed -$14K – 321
2020
Q2 		$14K Buy
+1,750
New +$13.9K ﹤0.01% 681

Other funds holding ACHV

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HR
Hayden Royal Charlotte, North Carolina $42.7M AUM 33.86% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnus Financial Group's ACHV Position: Q3 2020 in Review

Magnus Financial Group sold out of Achieve Life Sciences (ACHV) in Q3 2020, closing a stake of 1,750 shares — an estimated $14K sold.

Magnus Financial Group first reported a position in ACHV in Q2 2020 and held it in 1 quarter. The position peaked at $14K in Q2 2020. 13 funds tracked by Wall St. Rank hold ACHV as of Q3 2020.

  • Magnus Financial Group reported no remaining Achieve Life Sciences position as of Q3 2020 after selling out during the quarter.
  • Magnus Financial Group sold 1,750 Achieve Life Sciences shares in Q3 2020, an estimated $14K.
  • Magnus Financial Group first reported a position in Achieve Life Sciences in Q2 2020 and held it in 1 quarter.
  • Magnus Financial Group's Achieve Life Sciences position peaked at $14K in Q2 2020.
  • 13 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2020.

Based on Magnus Financial Group's 13F filing for Q3 2020, filed 5 Nov 2020.